{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-193925","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.608982+00:00","generated_at":"2026-05-15T00:57:29.913715+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"confidence":"high","headline":"Indivior Q1 net revenue $317M (+19% YoY); raises FY2026 guidance","bullets":["Q1 GAAP net income $89M ($0.69 EPS); non-GAAP net income $123M ($0.96 EPS).","SUBLOCADE net revenue $232M (+32% YoY) driven by 20% dispense unit growth.","Record Q1 adjusted EBITDA $164M (+112% YoY); cash and investments $201M.","Raised FY2026 guidance: net revenue $1.215-1.285B; adj. EBITDA $620-660M.","Discontinued INDV-6001 development; INDV-2000 failed Ph2 OUD endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-193925","json":"https://secwatch.observer/filing/0001193125-26-193925.json","markdown":"https://secwatch.observer/filing/0001193125-26-193925.md","text":"https://secwatch.observer/filing/0001193125-26-193925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000119312526193925/0001193125-26-193925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000119312526193925/d40828d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:57:29.913715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}